Inhibition of Sphingosine Kinase-2 in a Murine Model of Lupus Nephritis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Snider, Ashley J ^a,b   Ruiz, Phillip ^c   Obeid, Lina M ^a,b   Oates, Jim C ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC 294640; ALBUMIN; PHOSPHOTRANSFERASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 2; THROMBOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HOMING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FEMALE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PATHOGENESIS; PROTEINURIA; TISSUE DISTRIBUTION; TISSUE LEVEL;

ADAMANTANE; ALBUMINS; ANIMALS; CELL SEPARATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; ISOENZYMES; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MICE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRIDINES; SPHINGOLIPIDS; SPLEEN; THROMBOXANE B2;

MURINAE; MUS;

EID: 84871858878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053521     Document Type: Article

References (30)

1. Dooley MA, Hogan S, Jennette C, Falk R, (1997) Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney International 51: 1188-1195.
2. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE, (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25: 689-695.
3. Han TS, Schwartz MM, Lewis EJ, (2006) Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus 15: 71-75.
4. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, et al. (2000) Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275: 19513-19520.
5. Wenderfer SE, Stepkowski SM, Braun MC, (2008) Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int 74: 1319-1326.
6. Ando S, Amano H, Amano E, Minowa K, Watanabe T, et al. (2010) FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun 394: 804-810.
7. Hannun YA, Obeid LM, (2008) Principles of bioactive lipid signaling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150.
8. Zeidan YH, Hannun YA, (2007) Translational aspects of sphingolipid metabolism. Trends Mol Med 13: 327-336.
9. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, et al. (2001) Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60: 653-663.
10. Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, et al. (1998) Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. Journal of the American Society of Nephrology 9: 1202-1212.
11. Watson L, Tullus K, Marks SD, Holt RC, Pilkington C, et al. (2012) Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus. J Clin Immunol 32: 1019-1025.
12. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, et al. (2002) Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707-716.
13. Alperovich G, Rama I, Lloberas N, Franquesa M, Poveda R, et al. (2007) New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16: 18-24.
14. Budde K, Schutz M, Glander P, Peters H, Waiser J, et al. (2006) FTY720 (fingolimod) in renal transplantation. Clin Transplant 20Suppl 17: 17-24.
15. Theofilopoulos AN, Dixon FJ, (1985) Murine models of systemic lupus erythematosus. Advances in Immunology 37: 269-390.
16. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, et al. (2010) Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333: 129-139.
17. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, et al. (2008) Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 53: 997-1012.
18. Smith CD, French KJ, Xia Z (2007) Sphingosine kinase inhibitors and methods of their use. In: US Patent Office P, editor. United States.
19. Sekine H, Graham KL, Zhao S, Elliott MK, Ruiz P, et al. (2006) Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J Immunol 177: 7423-7434.
20. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, et al. (2010) Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Adv Exp Med Biol 688: 46-59.
21. Oates JC, Ruiz P, Alexander A, Pippen AM, Gilkeson GS, (1997) Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol 83: 86-92.
22. Gilkeson GS, Ruiz P, Grudier JP, Kurlander RJ, Pisetsky DS, (1989) Genetic control of inflammatory arthritis in congenic lpr mice. Clin Immunol Immunopathol 53: 460-474.
23. Zhang XK, Gallant S, Molano I, Moussa OM, Ruiz P, et al. (2004) Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol 173: 6481-6489.
24. Oates JC, Farrelly LW, Hofbauer AF, Wang W, Gilkeson GS, (2007) Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. Arthritis Rheum 56: 3738-3747.
25. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, et al. (2000) Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. Journal of Immunology. 164: 786-794.
26. Baker DA, Barth J, Chang R, Obeid LM, Gilkeson GS, (2010) Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis. J Immunol 185: 2570-2579.
27. Kelley VE, Sneve S, Musinski S, (1986) Increased renal thromboxane production in murine lupus nephritis. Journal of Clinical Investigation 77: 252-259.
28. Spurney RF, Bernstein RJ, Ruiz P, Pisetsky DS, Coffman TM, (1991) Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. Prostaglandins 42: 15-28.
29. Taha TA, Argraves KM, Obeid LM, (2004) Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim Biophys Acta 1682: 48-55.
30. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A, (2007) FTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism. Br J Pharmacol 150: 943-950.